加强百日咳研究和防控,维护公众疫苗接种信心——关注效价指标不合格疫苗事件及其长期影响

Enhance research, prevention and control of pertussis for protecting public confidence in vaccination: focus on the adverse events of vaccine with insufficient potency and its long-term impacts

摘要:

2017年11月3日，食品药品监管总局报告在药品抽样检验中检出两家公司的两个批次百白破疫苗效价指标不符合标准规定，可能影响免疫保护效果。当前国内百日咳存在病例增多趋势，并可能持续数年，这一变化易与疫苗效价不足事件联系起来，可能持久的影响公众对疫苗接种的积极性。百日咳再现的全球大环境、既往对国内百日咳的低估、检测方法的推广、对百日咳认识的变化、年长儿和成人百日咳的发现、流行菌株抗原性的变化等因素都可以导致今后百日咳病例明显增多。卫生科研和临床工作者应提高认识，科学评估疫苗效价不足事件对百日咳流行病学的影响，维护和提升公众疫苗接种信心。

Abstract:

On November 3, 2017, the China Food and Drug Administration reported that the potency indexes of two batches of diphtheria-pertussis-tetanus vaccines produced by two companies did not reach the requirements. Insufficient potency could affect the protection effect of these vaccines immunization. Currently, pertussis cases have already showed an increasing trend in China and could last for several years. Such an increase could be linked to these adverse events of vaccine with insufficient potency, which could become an evidence to challenge or deny the effectiveness of vaccination, and brings a persistent inhibition of the public's acceptance for vaccination. The wider global context of pertussis resurgence, previous underestimate on the domestic pertussis, the promotion of detection methods, the change of knowledge about pertussis, the confirmation of pertussis in elder children and adults, the antigenicity variation of pertussis strains could lead to a significant increase of pertussis cases. Health researchers and clinical workers should raise awareness about these factors, and assess rationally the impact of vaccine titer deficiency on pertussis epidemiology for maintaining and promoting public confidence in vaccination.